NeuroSense Therapeutics (NeuroSense Therapeutics) Cash Flow from Discontinued Operations : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NeuroSense Therapeutics Cash Flow from Discontinued Operations?

Cash flow from discontinued operations is the cash received by a company that comes from the sale of part of business.

NeuroSense Therapeutics's cash flow from discontinued operations for the three months ended in Dec. 2023 was $0.00 Mil. It means NeuroSense Therapeutics received $0.00 Mil from the sale of part of business quarterly. NeuroSense Therapeutics's cash flow from discontinued operations for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

NeuroSense Therapeutics Cash Flow from Discontinued Operations Historical Data

The historical data trend for NeuroSense Therapeutics's Cash Flow from Discontinued Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroSense Therapeutics Cash Flow from Discontinued Operations Chart

NeuroSense Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow from Discontinued Operations

NeuroSense Therapeutics Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash Flow from Discontinued Operations	Get a 7-Day Free Trial										-	-	-	-	-

NeuroSense Therapeutics Cash Flow from Discontinued Operations Calculation

Cash received by a company that comes from the sale of part of business.

Cash Flow from Discontinued Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

NeuroSense Therapeutics Cash Flow from Discontinued Operations Related Terms

Thank you for viewing the detailed overview of NeuroSense Therapeutics's Cash Flow from Discontinued Operations provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroSense Therapeutics (NeuroSense Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroSense Therapeutics Ltd (NAS:NRSN) » Definitions » Cash Flow from Discontinued Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

11 HaMenofim Street, Building B, Herzliya, ISR, 4676670

Website

https://www.neurosense-tx.com

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.